GSK’s Post

#News for #investors and #media: ViiV Healthcare, our specialist HIV company, are presenting over 20 abstracts from our innovative pipeline and portfolio of medicines at #AIDS2024, as well as showcasing our commitment to the #HIV community. Find out more: https://www.gsk.com/en-gb/

🚢 Now shipped: Flu doses for this upcoming season have left the warehouse! July might not be when most of us start thinking about the flu, but in order to protect people from influenza, we’re working proactively to ensure a steady supply of vaccines to help protect people from this illness. As part of our commitment to preventative healthcare, we’re helping families everywhere stay ahead of the flu. 💪 Details: https://gsk.to/3WiiXRR #FluVaccine #StayAhead #FluIsAFamilyAffair

“Healthcare is like a lightning rod — it's where gender equity and a thriving future meet. Because if women have a voice, education, and economic power, they will have access to health.” In partnership with Devex and ViiV Healthcare, Deborah Waterhouse discusses the pressing issue of discrimination and stigma faced by many women in lower-income countries, when it comes to accessing healthcare. Deborah also shares what we’re doing to help tackle the roots of health inequality through our work with partners such as mothers2mothers and through collaborations like the Gender Equality Fund. Read more from Deborah, here 👉 https://gsk.to/3zwrJTm

A series of lab tests diagnosed Andrew with #myelofibrosis (MF). Like many people who live with MF, managing this #bloodcancer can be challenging, requiring support from family and an expert care team. Throughout Andrew’s experience, self-advocacy and taking an active role in the management of his cancer with his wife and care partner, Esther, by his side have been key to living his fullest life. How does Andrew work with others to get ahead of this cancer? Learn more in WebMD: https://gsk.me/3VnW1z0

📢 Brazil and Thailand become the first malaria-endemic countries to launch new single-dose relapse prevention medicine for Plasmodium vivax (P. vivax) malaria    P. vivax is the dominant malaria parasite in many countries outside of sub-Saharan Africa and is characterised by clinical relapses. Without treatment for the latent liver-stage infection, patients experience repeated bouts of illness, imposing significant physical, economic, and social burdens on both individuals and communities. Relapses also increase the disease burden and the potential for onward transmission, ultimately impeding global efforts to eliminate malaria.     Developed through a longstanding partnership Medicines for Malaria Venture, tafenoquine, co-administered with chloroquine, offers a new potential treatment option for vulnerable populations who are disproportionately affected by this disease.     By continuing to invest in global health R&D, strengthening healthcare systems, and enabling access to healthcare in lower-income countries, together with our partners we can help change the trajectory of malaria.    #ChangeTheTrajectory #Malaria #GlobalHealth #ZeroMalaria 

#News for #investors and #media: Today we announced a new licensing agreement with CureVac. This is our latest investment in vaccine platform technologies, allowing us to match the best platform to each pathogen and help prevent illness in more people around the world. Read more: https://gsk.to/4eOUVoJ

We’re highlighting the importance of early action to help prevent irreversible organ damage in people with lupus. Global experts are recognising the extensive data to support the timely use of evidence-based treatments to help reduce the risk of permanent kidney damage. Learn more at our dedicated GSK site: https://gsk.to/3L15zew

Antimicrobial resistance is escalating, posing significant threat to humanity and challenges to health systems around the world.

Today, we’ve signed a new 10-year energy deal in Singapore with Sembcorp which is set to increase our global purchased renewable electricity usage by 9% from 2025. With this new agreement, all three of our medicines and vaccines manufacturing sites in Singapore will be covered by 100% renewable electricity generated directly at the site and purchased through renewable energy certificates from solar projects. Our sites in Singapore are critical for the production of innovative medicines and vaccines for HIV, oncology and infectious diseases. We know that climate change is already having a negative impact on human health, and we are committed to playing our part in protecting the health of both people and the planet to help get ahead of disease together. #LCAW2024

"Can we end epidemics?" is a brand new 6-episode podcast series from ViiV Healthcare, in partnership with Foreign Policy. Episode 5, ‘Reaching New Heights,’ brings together GSK’s Fiona Smith-Laittan and AMREF’s Dr Mercy Mwangangi to discuss: 🌍 What it takes to deliver health impact at scale? 💡 Why must global health innovation be accelerated? 🤝 And how can partnerships help build, strengthen and future-proof health systems? Take a listen wherever you get your podcasts! Or find out more, here: https://gsk.to/3RHnk6s